Marketing - Clinical Research Informer

Is biotech facing a long bear market?

Pharmaceutical Technology

JULY 6, 2022

Talks of a bear market in the biotech sector do not seem to pass, with news of companies falling into administration and layoffs becoming a recurrence. Just last week, trading for 4D Pharma , a British biotech, was suspended on the London Stock Exchange’s Alternative Investment Market , and the company will be delisted from NASDAQ on July 7.

Marketing

Marketing Gene Therapy Manufacturing Pharma Companies

Osteoporosis market expected to reach $17.9bn across 7MM by 2033

Pharmaceutical Technology

JUNE 24, 2024

The osteoporosis market is expected to grow at a compound annual growth rate of 5.4% The osteoporosis market is expected to grow at a compound annual growth rate of 5.4%

Marketing

Marketing Drugs

Current and future players in the lupus market

Pharmaceutical Technology

JANUARY 23, 2023

As such, the SLE and LN marketplace is dominated by generics, and GSK’s Benlysta and AstraZeneca’s Saphnelo are the only drugs that have gained marketing approval specifically for SLE in more than 50 years. In previous years, Benlysta has managed to grow the lupus market in terms of value, having generated approximately $492.9m

Marketing

Marketing Production Drugs Trials

Entrance of novel therapies will drive Niemann-Pick type C disease market growth

Pharmaceutical Technology

JULY 26, 2022

According to GlobalData’s recent Niemann-Pick Type C (NPC): Opportunity Analysis and Forecast to 2031 report, the NPC market is expected to see significant growth during 2021–31. This sales growth will be in line with a steadily increasing disease prevalence and the entrance of novel agents into the market.

Marketing

Marketing Gene Branding Clinical Development

Sandoz’s Afqlir gains EC marketing authorisation for retinal diseases

Pharmaceutical Technology

NOVEMBER 18, 2024

The EC has granted marketing authorisation for Sandoz's Afqlir for the treatment of various retinal diseases.

Marketing

5 things to look for in a marketing analytics partner

Bio Pharma Dive

OCTOBER 23, 2023

Effective marketing measurement requires objectivity, connected data, transparency, a track record of innovation and a proven ability to execute.

Marketing

GSK speeds up the race to bring first RSV vaccine for older adults to market

Pharmaceutical Technology

OCTOBER 31, 2022

If approved, GSK’s GSK-3844766A will be the first vaccine to reach the market for the prevention of RSV in older adults, gaining a significant first-mover advantage. The post GSK speeds up the race to bring first RSV vaccine for older adults to market appeared first on Pharmaceutical Technology.

Vaccination

Vaccination Vaccine Marketing Trials

EC grants marketing authorisation for Sandoz’s biosimilar Hyrimoz

Pharmaceutical Technology

APRIL 3, 2023

The European Commission (EC) has granted marketing authorisation for Sandoz’s biosimilar Hyrimoz (adalimumab) citrate-free high-concentration formulation (HCF). With eight marketed biosimilars, Sandoz is offering the broadest biosimilar portfolio and is the leading biosimilars company in Europe, with more than two decades of experience.

Marketing

Marketing Medicine Packaging Packaging

Lotus Pharmaceuticals and Teraju Pharma link for marketing in Malaysia

Pharmaceutical Technology

JUNE 12, 2023

Lotus Pharmaceuticals and Teraju Pharma have entered a strategic partnership to market Lotus’s products in a range of therapeutic areas in Malaysia. Teraju Pharma will be responsible for marketing and promoting the products using its relationships and infrastructure.

Marketing

Marketing Production Branding Manufacturing

Lilly market value soars on higher sales, obesity drug potential

Bio Pharma Dive

AUGUST 8, 2023

The Indianapolis drugmaker is now worth more than $500 billion, higher than any other pharmaceutical company, as analysts project lucrative markets for its obesity and Alzheimer's drugs.

Marketing

Marketing Sales Drugs

Top 20 biopharmas’ market cap up 4.3% in Q2 2024 as GLP-1 drug innovators hold top spots

Pharmaceutical Technology

AUGUST 20, 2024

The top 20 biopharmaceutical companies demonstrated resilience during the second quarter (Q2) of 2024 as global markets and investor optimism improved with anticipation of a potential interest rate cut from the US Federal Reserve.

Marketing

Marketing Drugs

Immuno-oncology market set to grow in billions, but access concerns remain

Pharmaceutical Technology

MAY 26, 2023

The immuno-oncology market continues to evolve as treatments establish their presence across different types of cancer, having seen approvals in multiple indications in the past decade. There are currently over 700 immuno-oncology products in Phase I-III of development in the eight major markets, said Chalk.

Marketing

Marketing Vaccine Vaccination Development

UK’s antibiotic subscription funding model – a route to market sustainability?

Pharmaceutical Technology

JULY 1, 2024

On 8 May, the UK was the world's first government to formally implement a new model for the funding and support of novel antibiotic commercialisation.

Marketing

How NVIDIA grew with the healthcare market instead of pushing into it

Pharmaceutical Technology

JULY 22, 2024

As the use of AI soared across healthcare, NVIDIA fit the bill in providing the necessary technology – and its stock tells the same story.

Marketing

Racing to the finish line: help for reducing risks, ensuring security and driving faster speed-to-market

Bio Pharma Dive

MAY 22, 2023

When pharma manufacturers are racing to bring a new product to market, catastrophic printing errors and mislabeled materials can have a significant impact on timelines and budgets.

Marketing

Marketing Manufacturing Production

EC announces EU pharma reform that cuts market exclusivity

Pharmaceutical Technology

APRIL 27, 2023

The European Commission’s (EC) long-anticipated pharma reform plans in the European Union have finally been unveiled , indicating a focus on improving access to medicines across the bloc while cutting down on market exclusivity.

Marketing

Marketing Medicine Production Clinical Trials

Kyverna sets plans for IPO in test of biotech market

Bio Pharma Dive

JANUARY 17, 2024

The offering is the fifth outlined by a biotech startup this month, suggesting companies are becoming more willing to gauge investors’ appetite for new stock offerings.

Marketing

Amylyx ventures into metabolic diseases market with $35.1m deal

Pharmaceutical Technology

JUNE 28, 2024

On 17 June, Amylyx acquired the rights to Eiger Biopharmaceutical’s experimental GLP-1 receptor antagonist, avexitide, for $35.1m.

Marketing

GSK to pull blood cancer drug from US market after study failure

Bio Pharma Dive

NOVEMBER 22, 2022

The British drugmaker has begun the process of withdrawing its multiple myeloma treatment Blenrep following a request from the FDA.

Marketing

Marketing Drugs

Opioid addiction market to reach $2.4 billion across 8MM by 2033

Pharmaceutical Technology

OCTOBER 18, 2024

Late-stage pipeline products could drive combined sales of approximately $171.4 million by 2033 in the 8MM.

Sales

Sales Marketing Production

Pharma’s data and analytics market forecast to reach to $2.1bn by 2028

Pharmaceutical Technology

DECEMBER 18, 2024

A new report identifies data content management as the primary driver of growth in the pharmaceuticals market.

Marketing

Novartis sales of Zolgensma gene therapy slow as market shifts

Bio Pharma Dive

OCTOBER 25, 2022

Treatment is now mostly of infants newly diagnosed with spinal muscular atrophy, as many of those previously eligible either already received Zolgensma or other drugs from Biogen and Roche.

Gene Therapy

Gene Therapy Sales Gene Marketing

RSV prophylactic market to reach $6.2bn in 8MM by 2030

Pharmaceutical Technology

DECEMBER 10, 2024

The respiratory syncytial virus (RSV) prophylaxis market across the eight major markets (8MM) - comprising the US, the five major European markets (France, Germany, Italy, Spain, and the UK), Japan, and Australia - is forecast to grow from $582m in 2020 to $6.2bn in 2030 at a compound annual growth rate of 26.7%, with the paediatric and adult segments (..)

Marketing

LEO Pharma’s eczema cream gains MHRA marketing authorisation

Pharmaceutical Technology

DECEMBER 5, 2024

LEO Pharma has gained marketing authorisation from the MHRA for Anzupgo to treat chronic hand eczema (CHE) in Great Britain.

Marketing

Private biotech M&A surges amid difficult IPO market

Bio Pharma Dive

JULY 22, 2024

Private biotech company acquisitions are on their fastest pace in years, a trend some in the industry say is driven by the abundance of mature, but not yet public, drug startups.

Marketing

Marketing Drugs

Sanofi/Regeneron’s Dupixent set to dominate COPD biologics market following FDA approval

Pharmaceutical Technology

SEPTEMBER 27, 2024

The US Food and Drug Administration (FDA) has announced the approval of Sanofi and Regeneron’s interleukin (IL)-4 and IL-13 monoclonal antibody, Dupixent, for the US market.

FDA Approval

FDA Approval Marketing Antibody Drugs

Eisai lowers Leqembi revenue forecast after rocky entry to market

Pharmaceutical Technology

NOVEMBER 8, 2024

Leqembi is approved for Alzheimer’s patients in multiple territories, but questions remain over its cost-effectiveness.

Marketing

Era of ADCs: Pharma companies innovate to stand out in a buzzing market

Pharmaceutical Technology

AUGUST 12, 2024

As antibody drug conjugate (ADC)-centred deals dominate the oncology space, biotechs are using newer targets and linkers to differentiate themselves.

Pharma Companies

Pharma Companies Antibody Marketing Drugs

FDA go-ahead for Verona Ohtuvayre transforms US COPD exacerbator market

Pharmaceutical Technology

JUNE 27, 2024

Data showed that Ohtuvayre significantly improved dyspnea compared to placebo in as little as six weeks and maintained this over 24 weeks.

Marketing

3 biotech executives on the year ahead: deals, drug pricing and the down market

Bio Pharma Dive

JANUARY 19, 2023

“What we’re experiencing now is the aftershock of the party that went on for the last three years,” said Ovid CEO Jeremy Levin in a BioPharma Dive panel that included former Sage head Jeff Jonas and biotech entrepreneur Greg Verdine.

Marketing

Marketing Drugs

Pfizer to pull sickle cell drug from market, shut down trials

Bio Pharma Dive

SEPTEMBER 26, 2024

The withdrawal comes as trial results indicate safety concerns with the drug, Oxbryta, which was first approved in the U.S.

Trials

Trials Drugs Marketing

Novo Nordisk aims for market domination, boasts $1.5bn obesity sales in Q1

Pharmaceutical Technology

MAY 2, 2024

Novo Nordisk noted a 22% boost in sales owing to increased sales of GLP-1 agonists and other obesity products.

Sales

Sales Marketing Production

How NIVIDIA grew with the healthcare market instead of pushing into it

Pharmaceutical Technology

JULY 22, 2024

As the use of AI soared across healthcare, NVIDIA fit the bill in providing the necessary technology – and its stock tells the same story.

Marketing

Top 20 biopharmas’ market cap rises 2% in Q3 2024 amid flurry of drug approvals

Pharmaceutical Technology

NOVEMBER 6, 2024

The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor optimism improved following the interest rate cuts by the US Federal Reserve in September 2024.

Marketing

Marketing Drugs

Inside the growing precision therapy market and the crucial role of pDNA manufacturing

Pharmaceutical Technology

JANUARY 21, 2024

CDMOs, who cater to the requirements of multiple companies and develop platform processes to achieve the much-needed economy of scale, are being seen as a possible solution.

Manufacturing

Manufacturing Marketing Development

Heart failure market estimated to grow, driven by pipeline agents aimed at unmet needs

Pharmaceutical Technology

JANUARY 6, 2025

The heart failure market is expected to grow at a 9.6% CAGR from $13.5bn in 2022 to $33.7bn in 2032 in the 7MM.

Marketing

Q&A: Tackling the rise of fake anti-obesity drugs on the market

Pharmaceutical Technology

DECEMBER 5, 2023

Professor Timothy Mackey talks about the recent reports of fraudulent Ozempic pens and the challenges in chasing drug counterfeiters.

Drugs

Drugs Marketing

Signal: Novo Nordisk market cap higher than Danish GDP due to obesity drugs

Pharmaceutical Technology

SEPTEMBER 1, 2023

Novo Nordisk's obesity drugs are driving Danish growth as well as record profits as the company becomes second-most valuable in Europe.

Drugs

Drugs Marketing

EC marketing authorisation granted to Pfizer’s HYMPAVZI for haemophilia

Pharmaceutical Technology

NOVEMBER 21, 2024

The EC has granted marketing authorisation for Pfizer's anti-tissue factor pathway inhibitor (anti-TFPI), HYMPAVZI to treat haemophilia.

Marketing

Imitation Ozempic Is Flooding The Market: Here’s What You Need to Know

AuroBlog - Aurous Healthcare Clinical Trials blog

OCTOBER 15, 2024

(Abdullah Durmaz/Getty Images) In just a few years, brand-name injectable drugs such as Ozempic, Wegovy, Mounjaro and Zepbound have rocketed to fame as billion-dollar annual sellers for weight loss as well as to control blood sugar levels and reduce the risk of heart disease. But the price of these injections is steep: They cost about […]

Marketing

Marketing Branding Drugs Clinical Trials

Amylyx ALS drug fails crucial study, putting company’s future in doubt

Bio Pharma Dive

MARCH 8, 2024

The results have led Amylyx to pause promotion of Relyvrio and potentially pull it from the market in the coming weeks, a major blow to the company and ALS patients.

Drugs

Drugs Marketing

Biotech startup Structure pulls off rare IPO, raising $161M

Bio Pharma Dive

FEBRUARY 2, 2023

The company’s lead drug could be an oral alternative to marketed diabetes and obesity drugs from Novo Nordisk and Eli Lilly.

Marketing

Marketing Drugs

'The music stopped': Biotech rout leaves drug startups grounded as demand slumps for IPOs

Bio Pharma Dive

FEBRUARY 6, 2022

For the first time in years, biotechs no longer have an easy path onto Wall Street, a market reversal that could change what the next generation of young drugmakers looks like.

Drugs

Drugs Marketing

As biotech retreats, gene therapy companies retrench and redraw plans

Bio Pharma Dive

MARCH 24, 2022

At least nine biotechs working in cell or gene therapy have announced layoffs, cost cuts or restructured their research since December — restructurings that have coincided with a stock market downturn.

Gene Therapy

Gene Therapy Gene Marketing Research

Is biotech facing a long bear market?

Osteoporosis market expected to reach $17.9bn across 7MM by 2033

Trending Sources

Current and future players in the lupus market

Entrance of novel therapies will drive Niemann-Pick type C disease market growth

Sandoz’s Afqlir gains EC marketing authorisation for retinal diseases

5 things to look for in a marketing analytics partner

GSK speeds up the race to bring first RSV vaccine for older adults to market

EC grants marketing authorisation for Sandoz’s biosimilar Hyrimoz

Lotus Pharmaceuticals and Teraju Pharma link for marketing in Malaysia

Lilly market value soars on higher sales, obesity drug potential

Top 20 biopharmas’ market cap up 4.3% in Q2 2024 as GLP-1 drug innovators hold top spots

Immuno-oncology market set to grow in billions, but access concerns remain

UK’s antibiotic subscription funding model – a route to market sustainability?

How NVIDIA grew with the healthcare market instead of pushing into it

Racing to the finish line: help for reducing risks, ensuring security and driving faster speed-to-market

EC announces EU pharma reform that cuts market exclusivity

Kyverna sets plans for IPO in test of biotech market

Amylyx ventures into metabolic diseases market with $35.1m deal

GSK to pull blood cancer drug from US market after study failure

Opioid addiction market to reach $2.4 billion across 8MM by 2033

Pharma’s data and analytics market forecast to reach to $2.1bn by 2028

Novartis sales of Zolgensma gene therapy slow as market shifts

RSV prophylactic market to reach $6.2bn in 8MM by 2030

LEO Pharma’s eczema cream gains MHRA marketing authorisation

Private biotech M&A surges amid difficult IPO market

Sanofi/Regeneron’s Dupixent set to dominate COPD biologics market following FDA approval

Eisai lowers Leqembi revenue forecast after rocky entry to market

Era of ADCs: Pharma companies innovate to stand out in a buzzing market

FDA go-ahead for Verona Ohtuvayre transforms US COPD exacerbator market

3 biotech executives on the year ahead: deals, drug pricing and the down market

Pfizer to pull sickle cell drug from market, shut down trials

Novo Nordisk aims for market domination, boasts $1.5bn obesity sales in Q1

How NIVIDIA grew with the healthcare market instead of pushing into it

Top 20 biopharmas’ market cap rises 2% in Q3 2024 amid flurry of drug approvals

Inside the growing precision therapy market and the crucial role of pDNA manufacturing

Heart failure market estimated to grow, driven by pipeline agents aimed at unmet needs

Q&A: Tackling the rise of fake anti-obesity drugs on the market

Signal: Novo Nordisk market cap higher than Danish GDP due to obesity drugs

EC marketing authorisation granted to Pfizer’s HYMPAVZI for haemophilia

Imitation Ozempic Is Flooding The Market: Here’s What You Need to Know

Amylyx ALS drug fails crucial study, putting company’s future in doubt

Biotech startup Structure pulls off rare IPO, raising $161M

'The music stopped': Biotech rout leaves drug startups grounded as demand slumps for IPOs

As biotech retreats, gene therapy companies retrench and redraw plans

Stay Connected